AbCellera Biologics (ABCL) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Legend Biotech (LEGN) over the past year, gaining 94.8% versus a loss of 39.1%. Over five years, ABCL leads with a -17.4% price change compared with -63.2% for LEGN. AbCellera Biologics is the larger company by market cap ($3.90 billion vs $3.64 billion), about 1.1 times the size.
Legend Biotech converts more of its revenue into profit, with a net margin of -28.8% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | LEGN |
|---|---|---|
| Share price | $12.02 | $18.71 |
| Market cap | $3.90B | $3.64B |
| 1-day change | -6.31% | -2.14% |
| YTD return | +251.46% | -12.05% |
| 1-year return | +94.81% | -39.13% |
| 5-year return | -17.39% | -63.17% |
| Forward P/E | — | 17.82 |
| EPS (TTM) | $-0.54 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $1.03B |
| Revenue growth (YoY) | +160.56% | +64.04% |
| Net income (latest FY) | $-146.41M | $-296.80M |
| Gross margin | — | 61.41% |
| Operating margin | -288.98% | -13.27% |
| Net margin | -194.88% | -28.85% |
| 52-week high | $15.02 | $37.50 |
| 52-week low | $2.75 | $16.24 |
| Distance from 52-week high | -19.95% | -50.11% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +38.94% | +148.53% |
| Average volume | 6.67M | 2.36M |
| Shares outstanding | 324.05M | 194.49M |
| Employees | 562 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed LEGN by 133.9 percentage points over the past year.
- Legend Biotech is more profitable, keeping -28.8 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +64.04%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
ABCL vs LEGN FAQ
Which is bigger, AbCellera Biologics or Legend Biotech?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.90B compared with $3.64B for Legend Biotech (LEGN).
Which stock has performed better over the past year, ABCL or LEGN?
ABCL returned +94.81% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.